Xantho Biotechnology Co., LTD Report issue

For profit Phase 2
Founded: Taipei City Taiwan (2014)

Organization Overview

First Clinical Trial
2020
NCT04369846
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Xantho Biotechnology Co., LTD

Active Ingredients

Drugs in Phase 2 Trials (1)

gm-xantho (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1